Well Woman Collective
Investment & Partnership Opportunity · 2026

Ancient Wisdom,
Modern Science

A new category in women's hormonal wellness, built from the inside out
A precision women's wellness platform — a broad-spectrum phytocannabinoid suppository range and a member subscription — supporting the endocannabinoid system through every stage of a woman's hormonal life.
Stage
Live · Pilot Running
Raising
Up to $150K, then $500K
R&D Invested
$270,000+
Gross Margin
71–80%
ConfidentialWell Woman Collective · In formation
01 / 11
The Problem

Women in hormonal transition are still searching.

1
The scale is enormous. Over a billion women are in menopause globally, and perimenopause — which begins a decade earlier — affects tens of millions more.
2
The options fall short. Hormone therapy carries real risk and is off the table for many; OTC supplements underdeliver; the wellness aisle is single-symptom and fragmented.
3
Nothing treats the whole picture. No single, coherent platform addresses the underlying biology of this transition.
1B+
Women in Menopause Globally
80–90%
of Women 18–55 Have Monthly Symptoms
02 / 11
The Solution

Support the system, not just the symptom.

A broad-spectrum, THC-free, non-hormonal suppository at the center of a membership platform.

Well Woman Collective supports the endocannabinoid system — the body's own balancing network for mood, sleep, stress, and hormonal rhythm. It works with a woman's biology rather than adding hormones from outside, making it a genuine option for the large group of women who cannot or choose not to use HRT — wrapped in a membership that turns one purchase into a lasting relationship.

03 / 11
Why Now

The category is inflecting — and capital is following.

Named the frontier

In 2025 STAT News identified perimenopause as the fastest-growing category in women's health investment.

Incumbents piling in

Hims & Hers launched a perimenopause line and Flo Health a Perimenopause Score — both in late 2025.

We are ready now

The formulation is complete and owned as the market converges — timing none of the new entrants can undo.

The window is open. Demand is enormous and underserved, attention is peaking, and Well Woman Collective arrives commercially ready with a mechanism and model competitors cannot replicate.

04 / 11
The Market

A $35.6B market by 2032.

The global menopause market was $21.4B in 2025 and is projected to reach $35.6B by 2032 at 7.5% CAGR, with North America holding 37% of share. The CBD women's-health serviceable market alone is tracking toward $14B by 2034.

Roughly 1.3 million US women enter menopause every year — a large, renewing, underserved demand base.

$21.4B $35.6B 2025 2032 7.5% CAGR ▲
05 / 11
The Product

A formulation built for precision — complete and owned.

◆
12-cannabinoid broad-spectrum complex at 120–150mg per unit — the entourage effect, not a single-compound isolate.
◆
70–90% bioavailability. Suppository delivery bypasses liver metabolism versus 6–20% for oral CBD.
◆
THC-free and Farm-Bill compliant. In-house production at launch, GMP co-packer at scale.
◆
A full range. Suppository anchor plus topical and sublingual companions, $48–$285.
12
Cannabinoids · Broad-Spectrum
70–90%
Bioavailability
0%
Detectable THC
Owned
Formulation, Outright
06 / 11
Business Model

Product margin plus recurring membership.

Two tracks: a public storefront at MSRP, and a membership platform — six guided wellness modules, community, and member pricing. The product is the anchor; the membership is the moat.

A full-stack annual member generates $1,000+ in Year-1 gross contribution across subscription and product, over relationships that run 18–36 months.

At launch At co-packer scale 72% 80% → Cash-generative from first sales
07 / 11
Traction

Not a concept. A live business.

✓
Complete & owned. $270,000+ and five years of R&D behind the formulation.
✓
Real-world data. A pilot with real participants is running; early self-reported feedback is consistently positive.
✓
Launch already funded by the founding partners — this raise is growth capital, not survival capital.
M6 M12 M18 M24 M36 50 600 ~2,000
Modeled member build under the full growth scenario
08 / 11
Competitive Advantage

A position no one else holds.

Clinical-grade potency and a broad-spectrum profile, embedded in a membership platform — a combination that does not exist elsewhere.

Brandmg / UnitProfile$ / mgMembership
Well Woman Collective120–150mg12-cannabinoid broad-spectrum$0.05Full platform
Foria Relief100mgCBD only$0.06None
Hello Again~25mgFull-spectrum w/ THC$0.28None
Healing Rose100mgCBG & CBD only$0.05None

4–6× better value per mg than the nearest broad-profile competitor, and the only offering with a membership moat.

09 / 11
The Team

Science-led. Purpose-driven.

Jenny Wolfe
Jenny Wolfe
Founder · LMT #LA9661
Licensed massage therapist and holistic practitioner leading the member wellness experience.
Dr. Heather Vinet
Dr. Heather Vinet
Founding Partner · Chief Clinical Officer
Research scientist (BSE, ND, PhD) turned holistic medicine practitioner; published across immunology and regenerative medicine.
Barry Bonner
Barry Bonner
Founder & Formulation Developer
25 years in pharmaceutical and biotech development; five years of endocannabinoid formulation research.
10 / 11
The Ask

Two ways in. Launch is already funded.

Up to $150,000
Founding Raise
Participations of $10k, $15k, $20k or greater. Funds the early growth runway — inventory, platform, content, first influencer seeding.
$150K – $500K
Growth Raise · Social
Funds the full organic, content-led acquisition engine through to co-packer scale, where margins expand further.
Structured as equity and SAFE agreements; investors may take part in one or both. Specific terms, valuation, and exit framework are confirmed directly with each investor ahead of close. The 3–5× return is a target under the full growth scenario, not a promise.
11 / 11
Contact

Let's begin a conversation.

Barry Bonner
barry@bonnerbiotech.com
Founder & Formulation Developer
+1 415 515 1665 (cell)
Jenny Wolfe
manamassage.jenny@gmail.com
Founder
Dr. Heather Vinet
hvinet@scientificallynatural.com
Chief Clinical Officer
Entity
Well Woman Collective
New entity · in formation
These statements have not been evaluated by the Food and Drug Administration. Well Woman Collective products are not intended to diagnose, treat, cure, or prevent any disease. Financial projections are based on industry benchmarks and are not guarantees of future results. Investment involves risk; consult independent legal and financial advisors before deciding. A detailed memo with full financials, science, and risks is available on request. Well Woman Collective is a new company currently in formation.